menu

Challenging Cases in CKD Anemia: The Kidneys and Heart as Linked Parts

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Challenging Cases in CKD Anemia: The Kidneys and Heart as Linked Parts

1.00 credits
60 minutes
ReachMD Healthcare Image
Restart
Resume
Choose a format
Take Post-TestSkip straight to the post-test if you have already participated in this activity
Media formats available:
1.00 credits
Completing the pre-test is required to view this content.
Completing the pre-survey is required to view this content.
Details
Presenters
Comments
  • Overview

    Anemia in chronic kidney disease (CKD) is persistently undermanaged because current treatments have been linked with an increased risk for major cardiovascular events. They are also injectable or intravenous and definitely invasive, which no doubt limits patient acceptance. 

    Hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs) are a novel class of small-molecule oral drugs in late-phase development and under review by the FDA that are poised to provide an alternative treatment paradigm for patients with CKD-related anemia. Physicians and other clinicians who manage patients with anemia in CKD will need to be familiar with these novel agents and the data supporting their use in appropriately selected patients.

  • Disclosure of Conflicts of Interest

    Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any financial relationships with ineligible companies. All identified relevant financial relationships are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. All relevant financial relationships have been mitigated.

    The following faculty/planners reported the financial relationships or relationships to products or devices they have with ineligible companies related to the content of these CME activities:

    Ajay K. Singh,MBBS, FRCP, MBA
    Chair, Editorial Board: Nephrology Times
    Consultant: Bayer, GlaxoSmithKline, Zydus 

    Kirsten L. Johansen, MD
    Advisory Boards:
    Akebia, GlaxoSmithKline, Vifor Pharma

    The Integrity Continuing Education, Inc. planners and managers have nothing to disclose.

  • Target Audience

    This educational activity has been designed for nephrologists, endocrinologists, cardiologists, and internal medicine physicians involved in the management of patients with CKD. 

  • Learning Objectives

    Upon completion of this educational activity, participants should be able to:

    • Clarify the disease burden imposed by untreated or undertreated anemia in patients with CKD, including in racially diverse patients
    • Correlate the pathophysiology of anemia in CKD with viable therapeutic targets 
    • Identify appropriate candidates for emerging CKD-related anemia treatments among patients on or not on dialysis based on efficacy and safety data from recent clinical trials 
  • Accreditation and Credit Designation Statements

    Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    Integrity Continuing Education, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Disclaimer

    Disclosure of Unlabeled Use
    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. does not recommend the use of any agent outside of the labeled indications. 

    The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. 

    Disclaimer
    The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

  • Provider(s)/Educational Partner(s)

    This educational activity is provided by Integrity Continuing Education, Inc.

  • Commercial Support

    This educational activity is supported by an educational grant from GlaxoSmithKline.

  • Directions to Learner

    There are no fees for participating and receiving CME credit for this activity. During the period of October 14, 2022 through October 14, 2023, participants must:

    • Read the learning objectives
    • Complete the pretest
    • Study the educational activity
    • Complete the posttest and the evaluation form

    A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better. 

  • Contact Information

    For information about ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or cme@integrityce.com.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Recommended
Details
Presenters
Comments
  • Overview

    Anemia in chronic kidney disease (CKD) is persistently undermanaged because current treatments have been linked with an increased risk for major cardiovascular events. They are also injectable or intravenous and definitely invasive, which no doubt limits patient acceptance. 

    Hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs) are a novel class of small-molecule oral drugs in late-phase development and under review by the FDA that are poised to provide an alternative treatment paradigm for patients with CKD-related anemia. Physicians and other clinicians who manage patients with anemia in CKD will need to be familiar with these novel agents and the data supporting their use in appropriately selected patients.

  • Disclosure of Conflicts of Interest

    Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any financial relationships with ineligible companies. All identified relevant financial relationships are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. All relevant financial relationships have been mitigated.

    The following faculty/planners reported the financial relationships or relationships to products or devices they have with ineligible companies related to the content of these CME activities:

    Ajay K. Singh,MBBS, FRCP, MBA
    Chair, Editorial Board: Nephrology Times
    Consultant: Bayer, GlaxoSmithKline, Zydus 

    Kirsten L. Johansen, MD
    Advisory Boards:
    Akebia, GlaxoSmithKline, Vifor Pharma

    The Integrity Continuing Education, Inc. planners and managers have nothing to disclose.

  • Target Audience

    This educational activity has been designed for nephrologists, endocrinologists, cardiologists, and internal medicine physicians involved in the management of patients with CKD. 

  • Learning Objectives

    Upon completion of this educational activity, participants should be able to:

    • Clarify the disease burden imposed by untreated or undertreated anemia in patients with CKD, including in racially diverse patients
    • Correlate the pathophysiology of anemia in CKD with viable therapeutic targets 
    • Identify appropriate candidates for emerging CKD-related anemia treatments among patients on or not on dialysis based on efficacy and safety data from recent clinical trials 
  • Accreditation and Credit Designation Statements

    Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    Integrity Continuing Education, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Disclaimer

    Disclosure of Unlabeled Use
    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. does not recommend the use of any agent outside of the labeled indications. 

    The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. 

    Disclaimer
    The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

  • Provider(s)/Educational Partner(s)

    This educational activity is provided by Integrity Continuing Education, Inc.

  • Commercial Support

    This educational activity is supported by an educational grant from GlaxoSmithKline.

  • Directions to Learner

    There are no fees for participating and receiving CME credit for this activity. During the period of October 14, 2022 through October 14, 2023, participants must:

    • Read the learning objectives
    • Complete the pretest
    • Study the educational activity
    • Complete the posttest and the evaluation form

    A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better. 

  • Contact Information

    For information about ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or cme@integrityce.com.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Schedule6 Dec 2022